MDPI announces the publication of the following issue:
Mar. Drugs, Volume 11, Issue 5 (May 2013), Pages 1427-1762
PetroAlgae Inc. (otcpk:PALG), a global provider of licensed technology that produces micro-crops for renewable protein, feed, and fuel products announced today the completion of the first phases of two studies showing that PetroAlgae micro-crop protein could qualify as the first major new plant protein source for humans since soy protein entered the human diet in the 1950s.
PetroAlgae’s patent pending technology employs a hydroponic system using indigenous aquatic plants and is designed to enable its licensees to produce high-value protein, animal feed and a cost-effective alternative to fossil fuels, while absorbing carbon dioxide. Unlike most soy products, PetroAlgae protein is not produced from genetically modified (GMO) species; it is derived from renewable aquatic crops using no pesticides or heavy metals that would otherwise contaminate the products with residues. Moreover, by using a local, non-GMO species, the PetroAlgae licensed technology preserves the ecological integrity of the areas that are farmed, and it does not pollute soil or water.
The studies were performed at the College of Agriculture at Purdue University, under the direction of Dr. Mario Ferruzzi; by Dr. Fadi Aramouni of the College of Animal Sciences and Industry at Kansas State University; and by independent laboratories such as Craft Technologies, Inc.
Green Plains Renewable Energy, Inc. and BioProcess Algae, LLC have announced the successful completion of the first round of algae-based poultry feed trials. The algae strains produced for the feed trials demonstrated high energy and protein content that was readily available, similar to other high value feed products used in the feeding of poultry today.
The algae strains used in the feed trials were grown in BioProcess Algae’s Grower Harvester™ reactors, co-located with Green Plains’ ethanol plant in Shenandoah, Iowa. The test was conducted in conjunction with the University of Illinois, led by Dr. Carl M. Parsons, a leading expert in the field of poultry sciences.
Aqua Bio Technology (Oslo Axess : ABT) a Norwegian marine biotech firm developing, producing and selling patented marine based ingredients and technologies to the international cosmetic and skin care industry, today announced it has entered into a sales agreement of with a highly regarded Asian manufacturer of skin care products. As a part of the agreement, ABT will supply its bioactive ingredient Zonase X(TM) to be the key ingredient in a new product line the manufacturer will launch in January 2011.
The new line will consist of five products, developed in collaboration with ABT. The new skin care line will initially be introduced in the Asian markets through the manufacturer’s existing distribution channels. In addition, the manufacturer is also in discussion with distributors in Australia and selected European countries regarding launch in those markets.
Due to competitive reasons, the manufacturer has requested that it is not named until the products are launched. The reason is that the manufacturer considers Zonase X(TM) a novel and highly innovative technology.
It is important to understand that this is not a fisheries conference, it is a health conference, but one where the participants all share a common interest and will communicate information about the very latest medical research into all health aspects of the benefits of seafood. New discoveries and a deeper understanding of the health benefits of seafood are occurring at a rapid rate and this conference will highlight the very latest information available.
It is anticipated to attract up to 1,000 participants made up of the world’s leading health researchers, environmental researchers, medical practitioners, nutrition educators and policy-makers, probably some 50 or more countries will be represented, from the Americas and Europe to Asia and the South Pacific.
The conference will be supported by a Trade display of industry, scientific and health/environment exhibitors to ensure the attendees leave with the very latest knowledge in all these important areas. The conference program will embrace the public health and wellbeing by seeking presenters to deliver the latest development of these types of subjects: Obesity, Child Nutrition, Brain Nutrition, Health Benefits of Fish Consumption, Nutrition and Public Health, The role of fish and seafood in human cognitive development, Diabetes, Heart Health, education issues in nutrition and public health, and importantly Sustainability of Fisheries Resources and the future of aquaculture.
The Irish Farmers Assoiciation (IFA) Aquaculture and the Irish Sea Fisheries Board, Bord Iascaigh Mhara (BIM)’s Aquaculture division will host a special seminar in the Sheraton Hotel, Athlone on June 16, starting at 11.00am.
The seminar will be open to all seafood processors and aquaculture operators and will look at the two main issues on by-products through specialist talks and discussions: 1. Regulationof by-products and 2. Options and opportunities for disposal / sale.
Options for the industry for alternatives to rendering of seafood by-products are gradually coming on stream, including incineration, composting, anaerobic digestion and transformation into technical products. All of these areas will be looked at in detail at the seminar.
Last November, Chilkoot Fish and Caviar Inc. of Haines was hit with a complaint by the EPA that could cost the company the maximum civil penalty of $177,500 for continuously violating its waste discharge permit under the Clean Water Act over a period of four years.
In January 2007, Deep Creek Custom Packaging Inc. of Ninilchik was fined $10,500 by the EPA, also for improperly disposing of fish waste.
Under Clean Water Act regulations, fish processors must grind their waste to a size of a half-inch or less before discharge. Even under proper disposal, however, fish waste can impact the environment by creating “dead zones,” essentially sucking out oxygen needed for live fish to thrive.
The crackdown on fish waste discharges is of special concern for small companies that process less than 25 tons per day that cannot afford the multi-million dollar price tags for equipment deployed at large-scale operations that separates, dries and grinds waste into fishmeal for sale as a byproduct to the agriculture and aquaculture industries.
This is where entrepreneurs like Sandro Lane and Leo Pedersen and scientists such as Scott Smiley and Peter Bechtel come in. Lane and Pedersen have found creative ways to simultaneously turn previously discarded fish waste into economically valuable products while aiding small processors.
Bluewave Marine Ingredients is please to announce its new sanitary facility dedicated to the production of Fish Peptides for Feed / Food ingredient applications is up and running in So. America.
The sanitary grade facility began commercial scale production of Peptides this summer with Ecuadorian poultry/aquaculture clients being the first to incorporate PerfectDigestTM FPi into their feed formulas.
LiveFuels, based in California, is using their 10 million dollar in funding to try things differently in growing and harvesting algae. It feeds the algae to the fish and lets the fish work on harvesting it. After the fish fatten up, they are caught in nets and processed for oil and protein used in animal feed. LiveFuels is testing different breeds of fish and researching when would be the optimum time to harvest the fish.
Made mainstream by its role in human-genome mapping, genetic-trait analysis, and forensics, deoxyribonucleic acid is also playing a role as a biopolymer for the creation of novel photonic devices.
Andrew Steckl and colleagues at the University of Cincinnati have used DNA to improve the efficiency of organic light-emitting diodes (OLEDs) for illumination and displays. To make efficient biopolymers, a better understanding is needed of the chemical composition of the DNA material as it is synthesized from its low-density water environment to a dryer, condensed state. “DNA’s natural environment is water, but 99% of the [optoelectronic] devices we work on are solid-state,” says Andrew Steckl. While DNA in solution is being explored for use in optofluidic devices, Steckl sees three critical areas of research necessary to establish the commercial viability of DNA biopolymer-based photonic devices: ensuring an adequate material supply, perfecting the conversion from water-soluble to organic-solvent-soluble DNA, and controlling the “wet-to-dry” transition and understanding its effect on the DNA structure and properties.